SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

CCT129202

Item No. 29053

CAS Registry No.:	942947-93-5
Formal Name:	4-[6-chloro-2-[4-(dimethylamino) phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]-N-2-thiazolyl-1-piperazineacetamide
MF:	$C_{23}H_{25}ClN_8OS$
FW:	497.0
Purity:	≥98%
UV/Vis.:	λ_{max}: 267, 348, 404 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CCT129202 is supplied as a crystalline solid. A stock solution may be made by dissolving the CCT129202 in the solvent of choice, which should be purged with an inert gas. CCT129202 is soluble in the organic solvent DMSO at a concentration of approximately 3 mg/ml.

Description

CCT129202 is an Aurora kinase inhibitor that inhibits Aurora A and B by 82 and 60%, respectively, when used at a concentration of 1 µM in cell-free assays.[1] It is selective for Aurora A and B over a panel of 13 kinases at 1 µM. CCT129202 inhibits growth of COLO 205, SW620, HCT116, HT-29, KW12, HeLa, A2780, OVCAR-8, MDA-MB-157, and MB4-11 cancer cells (GI_{50}s = 0.08-1.2 µM). It induces DNA accumulation and cell cycle arrest at the G_2/M phase, as well as apoptosis in HCT116 cells. CCT129202 increases the accumulation of doxorubicin and rhodamine 123 in multidrug-resistant (MDR) KBv200 and MCF-7/adr cells and increases the susceptibility of MDR KBv200, MCF-7/adr, S1-M1-80, and HL60/adr cells to cisplatin (Item No. 13119) and doxorubicin (Item No. 15007).[2] *In vivo*, CCT129202 (100 mg/kg) reduces tumor growth in an HCT116 mouse xenograft model.[1] It also potentiates the antitumor effects of vincristine (Item No. 11764) in a KBv200 mouse xenograft model.[2]

References

1. Chan, F., Sun, C., Perumal, M., *et al.* Mechanism of action of the Aurora kinase inhibitor CCT129202 and *in vivo* quantification of biological activity. *Mol. Cancer Ther.* **6(12 Pt 1),** 3147-3157 (2007).
2. Cheng, C., Liu, Z.-G., Zheng, H., *et al.* Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202. *Mol. Pharm.* **9(7),** 1971-982 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM